Viral Vector Vaccines Market Surges: New Visual Insights Reveal Rapid Growth Through 2031 | Major players - Novartis, AstraZeneca, Abbott, GlaxoSmithKline Plc.

Market Overview:

The Viral Vector Vaccines Market is estimated to reach at a CAGR of 14% during the forecast period (2024-2031). The Market is growing due to rising demand for advanced vaccine platforms that enable rapid response to emerging infectious diseases, along with increasing investments in gene-based immunization technologies. According to DataM Intelligence Report.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/viral-vector-vaccines-market?sz

The Viral Vector Vaccines Market refers to the segment of biotechnology focused on vaccines that use modified viruses as delivery systems to introduce genetic material into host cells, triggering a strong immune response. This market includes development, manufacturing, and commercialization of viral vector-based vaccines for infectious diseases, cancer, and emerging health threats, driven by advances in gene therapy and vaccine innovation.

United States: Recent Developments of Viral Vector Vaccines Market

✅ November 2025: Pfizer and BioNTech's Comirnaty COVID-19 vaccine, utilizing viral vector technology, received full FDA approval for adults aged 65 and older and individuals aged 5-64 with underlying conditions, enhancing seasonal variant preparedness.

✅ October 2025: The U.S. viral vector and plasmid DNA manufacturing market grew to US$ 3.3 billion, driven by expanded biomanufacturing for gene therapy trials and vaccine production.

✅ September 2025: NIH funding advanced the "Generation Gold Standard" program, incorporating viral vector technologies for next-generation universal vaccine platforms.

Europe: Recent Developments of Viral Vector Vaccines Market

✅ November 2025: Europe solidified its 27% global share in viral vector manufacturing, supported by EMA frameworks facilitating clinical development for gene therapies and vaccines in countries like Germany and the UK.

✅ October 2025: EMA regulatory support boosted adoption of advanced bioprocessing for viral vectors, accelerating production efficiency for vaccinology and cell therapy applications.

✅ September 2025: Europe expanded vaccine contract manufacturing facilities, particularly in Germany, increasing capacity for viral vector-based vaccines amid rising R&D investments.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/viral-vector-vaccines-market?sz

FDA Approvals in 2025:

✅ Sept 1 and Dec 3, 2025. Major FDA vaccine activity in summer 2025 focused on updated mRNA COVID-19 vaccines (e.g., approvals/authorizations in late Aug 2025), but I found no FDA license/EUA announcements in Sept-Nov 2025 for adeno-vector / AAV / other viral-vector vaccines.

Mergers & Acquisitions in 2025:

✅ Oxford Biomedica (OXB) - acquisition of a commercial-scale viral-vector facility (Durham, North Carolina) - closed/announced 7 Oct 2025. This was an FDA-approved commercial viral-vector (AAV-focused) manufacturing site acquired from an RTP Operating (Resilience) subsidiary; it expands OXB's US GMP capacity and is explicitly described as a viral-vector manufacturing asset. (Major press releases and market/press coverage 7-8 Oct 2025).

Other manufacturing deals / activity affecting vector capacity (context during the period):

✅ Thermo Fisher and other CDMO players were publicly active in equipping / partnering on viral-vector manufacturing capacity in Q3-Q4 2025 (announcements in September 2025 about new facility equipment and partnerships to stand up vector plants). This reflects continued investment into viral-vector manufacturing capacity rather than vaccine approvals per se.

Regulatory Approvals / Regulatory policy changes (EMA / WHO / FDA policy) in 2025:

✅ EMA (CHMP) - September 15-18, 2025 meeting: CHMP published routine meeting highlights and recommended a set of medicines at its Sept meeting; I did not find a CHMP approval during that meeting that added a new viral-vector vaccine licence in the Sept-Nov window. (CHMP meeting highlights are available for Sept 15-18).

✅ WHO - I found WHO activity in September 2025 relating to Emergency Use Listings (EUL) for diagnostics and continued prequalification activity for mpox vaccines earlier - but no new WHO EUL or prequalification of a new viral-vector vaccine in Sept-Nov 2025. (WHO posted other EUL items in mid-Sept 2025, mainly diagnostics).

✅ FDA regulatory environment (policy signals) - late Nov 2025 reporting shows the FDA leadership proposing stricter vaccine approval protocols (reports Nov 2025). That policy environment - if implemented - could affect timelines for future vaccine approvals (including viral-vector vaccines). This was reported in mainstream press in late Nov 2025.

Major Players:

Key companies in the Viral Vector Vaccines market include:

Novartis
Sanofi Pasteur Inc. (Sanofi S/A)
AstraZeneca
CSL Ltd. (Seqirus)
Abbott
GlaxoSmithKline Plc.
Serum Institute of India Pvt. Ltd.
Pfizer
BioNTech
F.Hoffman La Roche Ltd

Segments Covered in the Viral Vector Vaccines Market:

By Vector Type: Adeno-associated virus, Retrovirus, Lentivirus, Adenovirus, Sendai virus.

By Route of Administration: Intramuscular, Subcutaneous.

By Application: Gene Therapy, Vaccinology Development.

By Distribution Channel: Hospitals, Vaccination center, Specialized clinics.

Regional Analysis for Viral Vector Vaccines Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=viral-vector-vaccines-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Viral Vector Vaccines market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Viral Vector Vaccines Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Viral Vector Vaccines market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Viral Vector Vaccines Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Viral Vector Vaccines market?

➠ Who are the global key manufacturers of the Viral Vector Vaccines Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Viral Vector Vaccines market opportunities and threats faced by the vendors in the global Viral Vector Vaccines Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Viral Vector Vaccines market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.